PT -期刊文章盟Burcu Zeydan AU -迪k . Deelchand盟Nirubol Tosakulwong盟——蒂莫西·g·Lesnick盟——玛丽·m·Machulda AU - David s . Knopman盟克利福德·r·杰克,小非盟-罗纳德·c·彼得森盟Gulin Oz盟Kejal Kantarci TI -先进1 h-mrs检测谷氨酸水平减少遗忘MCI (P4.093) DP - 2017年4月18日TA -神经病学PG P4.093 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P4.093.short 4100 - http://n.neurology首页.org/content/88/16_Supplement/P4.093.full所以Neurology2017 4月18日;88 AB -目的:比较的先进semi-localization绝热选择性调整(激光)质子核磁共振谱(1 h-mrs)协议优化与传统FASTMAP补偿点分辨光谱法(媒体)协议检测谷氨酸水平变化遗忘轻度认知障碍患者(aMCI)。背景:谷氨酸aMCI已经改变的结果不一致的使用常规方法1 h-mrs。一个高级semi-LASER协议优化FASTMAP匀场可能优于传统媒体协议识别早期谷氨酸aMCI改变,因为较小的化学位移位移错误和窄谱线宽。设计/方法:患者aMCI由于阿尔茨海默病(AD) (n = 14;= 79)和年龄,年龄中位数sex-matched临床正常对照组(CN;n = 32;年龄中位数= 80)以人群为基础的梅奥诊所研究衰老的招募3特斯拉1 h-mrs研究。包括,控制必须低淀粉样11日负荷c-pittsburgh复合B(加以)宠物(标准摄入值比;SUVr & lt; 1.4)和aMCI患者由于广告必须高淀粉样负载(PiB-PET SUVr≥1.4)。1 h-mrs体素包括先进的后扣带脑回(semi-LASER FASTMAP)和常规(媒体)协议,和代谢物的浓度计算校正后脑脊液体素的浓度。结果:CN中谷氨酸浓度组的方差较低semi-LASER协议相比,按协议(p = 0.001)。谷氨酸,谷氨酸/肌醇在aMCI比率是低于CN使用协议,但sla的数据具有统计上的显著差异和不与媒体(谷氨酸:sla p = 0.04,按p = 0.36; glutamate/myo-inositol: sLASER p=0.02, PRESS p=0.11).Conclusions: Utilization of an advanced MRS protocol with semi-LASER localization and FASTMAP shimming reduced the variance of glutamate levels in the control group, which in turn contributed to detection of decreased glutamate concentration in aMCI due to AD.Study Supported by:This study was funded by The Minnesota Partnership for Biotechnology and Medical Genomics and the NIH [R01 AG040042, P50 AG016574, U01 AG006786, C06 RR018898, R01 NS080816], The Elsie and Marvin Dekelboum Family Foundation, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program.Disclosure: Dr. Zeydan has nothing to disclose. Dr. Deelchand has nothing to disclose. Dr. Tosakulwong has nothing to disclose. Dr. Lesnick has nothing to disclose. Dr. Machulda has nothing to disclose. Dr. Knopman has received personal compensation for activities with Lundbeck Pharmaceuticals.Dr. Knopman has received research support from Lilly Pharmaceuticals, Biogen and TauRX. Dr. Jack has received personal compensation for activities with Janssen Research & Development, LLC by providing consulting services. Dr. Jack has received research support from the National Institutes of Health (R01-AG011378, RO1-AG041851, RO1-AG037551. Dr. Petersen received personal compensation for activities with Merck, Roche, Genentech, Biogen, and Eli Lilly and Co. Dr. Oz has nothing to disclose. Dr. Katarci has received royalty payments from Takeda.